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IMPORTANCE The US Food and Drug Administration recommends screening for the
HLA-B*1502 allele before initiation of carbamazepine therapy in patients of Asian ancestry,
but there remains unclear evidence of a relationship betweenHLA-B*1502 and
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) among
carbamazepine users, especially in some racial/ethnic populations.
OBJECTIVE To determine the relationship between the HLA-B*1502 allele and
carbamazepine-induced SJS and TEN.
DATA SOURCES A comprehensive search of the following data sources was performed
without language restriction from the inception of the database until January 8, 2013:
EMBASE, PubMed, clinicaltrials.gov, Cochrane Library, IPA (International Pharmaceutical
Abstracts), HuGENet (Human Genome Epidemiology Network), and CINAHL (Cumulative
Index to Nursing and Allied Health Literature), and the reference lists of identified studies.
STUDY SELECTION Inclusion criteria were studies that investigated the relationship between
HLA-B*1502 and carbamazepine-induced SJS and TEN and that reported sufficient data for
calculating the frequency ofHLA-B*1502 carriers among cases and controls. The search
yielded 525 articles, of which 16met the inclusion criteria. The studies included 227 SJS or
TEN cases, 602matched control subjects, and 2949 population control subjects.
DATA EXTRACTION AND SYNTHESIS Two reviewers independently extracted the following
data: study design, eligibility criteria, diagnostic criteria, patient demographics, genotype
distribution,HLA-B genotyping technique, selection of cases and controls, dosage of
carbamazepine and duration of use, and results of Hardy-Weinberg equilibrium in the control
group. The Newcastle-Ottawa Scale was used to assess the quality of studies. The overall
odds ratios (ORs) with corresponding 95% CIs were calculated using a random-effects model.
The primary analysis was based onmatched control studies. Subgroup analyses by
race/ethnicity were also performed.
MAIN OUTCOME ANDMEASURE The primary outcomewas carbamazepine-induced SJS and
TEN. The outcomemeasure is given as an overall OR.
RESULTS The summary OR for the relationship betweenHLA-B*1502 and carbamazepine-
induced SJS and TENwas 79.84 (95% CI, 28.45-224.06). Racial/ethnic subgroup analyses
yielded similar findings for Han-Chinese (115.32; 18.17-732.13), Thais (54.43; 16.28-181.96), and
Malaysians (221.00; 3.85-12 694.65). Among individuals of white or Japanese race/ethnicity,
no patients with SJS or TENwere carriers of theHLA-B*1502 allele.
CONCLUSIONS AND RELEVANCE We found a strong relationship between theHLA-B*1502
allele and carbamazepine-induced SJS and TEN in Han-Chinese, Thai, andMalaysian
populations.HLA-B*1502 screening in patients requiring carbamazepine therapy is warranted.
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S tevens-Johnson syndrome (SJS) and toxic epidermalnecrolysis (TEN) are life-threatening conditions affect-ing the skinandmucousmembranes.1 BothSJSandTEN
are characterized by blisters arising on purple macules. Le-
sions are widespread and usually predominate on the trunk
of the body. The percentage of skin detachment body surface
areadifferentiatesSJSandTEN.2Although the incidenceofSJS
and TEN is low (0.4-6 cases per million persons per year),1,3
mortality rates are as high as 5% to 12.5% for SJS, 33.3% for SJS
and TEN overlap, and 30% for TEN.1,4
The primary identifiable causative agent of SJS and TEN
ismedication use (almost 80%of cases).1 Other factors impli-
cated include chemicals, viral infection, immunizations, and
mycoplasma pneumonia. Several classes of medication have
been strongly associated with SJS and TEN, including antibi-
otics, antiepilepticdrugs,andxanthineoxidase inhibitors.1Car-
bamazepine is themost commoncause of SJS or TEN.5,6 AEu-
ropean study7 found that the risks of SJS or TEN among
carbamazepine and phenytoin users were more than 90 and
53 times greater than those of nonusers, respectively.
Multiple investigators have reported a relationship be-
tween HLA genes and SJS and TEN induced by carbamaze-
pine. Specifically, theHLA-B*1502 allele (OMIM142830.0002)
has been associated with carbamazepine-induced SJS and
TEN.8-11 In addition to carbamazepine, allopurinol can be a
causative agent of SJS andTEN, particularly among those car-
rying the HLA-B*5801 allele.12 Based on these observational
studies, the US Food and Drug Administration published an
alert to health care professionals that severe allergic skin re-
actions can be caused by carbamazepine use in patients with
theHLA-B*1502 allele and recommended screening for the al-
lele before initiation of carbamazepine therapy in patients of
Asian ancestry.13
Despite the alert from the US Food and Drug Administra-
tion, some studies9,11,14-16 have demonstrated no such asso-
ciation in the Japanese population. This difference likely re-
flects race/ethnicity variation, as well as nonreporting of less
severe cutaneous drug reactions.9,11,14-16 To fully understand
the relationshipbetweenHLA-B*1502 andSJS andTENamong
carbamazepineusers, a systematic review identifyingall stud-
ies assessing suchassociation is needed.A transparent and re-
producible process may be provided using a systematic re-
viewapproach.Thismethodcanelucidatepotential similarities
anddifferences thatmay explain the findings. Therefore, this
study was undertaken to systematically review all relevant
studies and to quantitatively synthesize themagnitude of the
relationship between the HLA-B*1502 allele and carbamaze-
pine-induced SJS and TEN.
Methods
Data Sources and Search Strategy
WesearchedEMBASE,PubMed,clinicaltrials.gov,TheCochrane
Library, IPA(InternationalPharmaceuticalAbstracts),HuGENet
(HumanGenomeEpidemiologyNetwork),andCINAHL(Cumu-
lativeIndextoNursingandAlliedHealthLiterature).Alldatabases
weresearchedfromtheirinceptionuntilJanuary8,2013.Searches
wereperformedusing keywords and synonyms forHLA-B and
carbamazepineandrelevant termsforSJSandTEN.ForPubMed
and The Cochrane Library, Medical Subject Headings were
searched for HLA-B and carbamazepine and for SJS and TEN.
Therewasno languageor studydesign restriction,butonlyhu-
man studies were included. Additional studies were retrieved
from the reference lists of the selected articles.
Study Selection
Two reviewers (W. Tangamornsuksan and R.S.) indepen-
dently assessed abstracts and titles retrieved from the com-
prehensive searches for study inclusion. The inclusion crite-
riawere studies that (1) investigated the relationship between
HLA-B*1502 and carbamazepine-induced SJS and TEN and
(2) reported sufficient data for calculating the frequency of
HLA-B*1502 carriers among cases and controls. Anydisagree-
ments were discussed until consensus between the 2 review-
ers could be reached.
Data Extraction andQuality Assessment
All articleswereextracted independentlyby the reviewers;dis-
crepancieswereresolvedbydiscussion.Thefollowingdatawere
extracted fromeach study: studydesign, eligibility criteria, di-
agnostic criteria, patient demographics, genotype distribu-
tion,HLA-B genotyping technique, selection of cases and con-
trols,dosageof carbamazepineanddurationofuse, and results
ofHardy-Weinbergequilibrium(astateofequilibriumunder the
mendelian law of genetic inheritance) in the control group.
Hardy-Weinberg equilibrium was tested to check if the in-
cluded individuals were in equilibrium for the frequencies of
genotypes.17,18 Equilibriumimplies that the included individu-
als are likely representative of thepopulation.19,20Weused the
Newcastle-OttawaScale21 toassess thequalityof thestudies in-
cluded in the review. This scale is an 8-item instrument, cat-
egorized into the following 3 domains: selection of partici-
pants, comparability between 2 groups, and the assessment of
exposures and outcomes. A system of stars is used to provide
quality ratings for studies.
Data Analysis
Theoverall odds ratios (ORs)with corresponding95%CIswere
calculated to determine the relationship between the pres-
ence of HLA-B*1502 in at least 1 allele and carbamazepine-
induced SJS and TEN. All analyses were performed with the
method by DerSimonian and Laird22 using a random-effects
model. The analyseswere also performed separately on stud-
ies using different types of control groups (eg, control sub-
jects obtained from the study [matched control study] or con-
trol subjects obtained from the population database
[population study]). The primary outcomemeasurewas ana-
lyzed using thematched control study. Subgroup analyses by
race/ethnicity were also performed to determine the robust-
ness of the findings. Statistical heterogeneitywas assessedvia
theQ statistic and I 2 tests.23P ≤ .10 indicatedheterogeneitybe-
tween studies. I 2 values of 25% and 50%denoted lowhetero-
geneity and moderate heterogeneity, respectively, across
studies.24 Funnel plot, Begg test, and Egger test were used to
evaluate publication bias.25,26
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Results
Study Selection
In total, 525 articles were identified by the search. Sixteen
articles14,16,27-40 met the inclusion criteria. Some SJS and TEN
cases included in thestudiesbyChungetal,9 Ikedaetal,15Wang
etal,41andKulkantrakornetal42werealso inthestudiesbyHung
et al,28 Kaniwa et al,29 Shi et al,36 and Tassaneeyakul et al,37 re-
spectively. In addition, 1 study43 and 2 abstracts44,45 poten-
tially met the inclusion criteria but lacked key information. Of
the original 525 articles, 16 remaining studies were included in
themeta-analysis (Figure 1). No additional articleswere identi-
fied via a review of the bibliographies of the included studies.
Study Characteristics
Characteristics of the included studies are summarized in
Table 1. The studies included 227 SJS or TENcases14,16,27-40; in
addition, therewere602matchedcontrol subjects14,28,30-32,35-40
and 2949 population control subjects.16,27,29,30,33,34 Eleven
studies14,28,30-32,35-40 were conducted using matched con-
trols,while 6 studies16,27,29,30,33,34 used thepopulation as con-
trols. Fifteen studies were conducted among Asian popula-
tions, including 1 study30 in Koreans, 1 study34 in Indians, 2
studies32,37 inThais, 2 studies27,38 inMalaysians, 3 studies16,29,35
in Japanese, and 6 studies28,31,36,39-41 in Han-Chinese. Two
studies14,34examined individualsofwhite race/ethnicity,while
3 studies27,31,33 evaluated multiethnic populations (Table 1).
Among studieshavingmatched controls, themeanages of
includedpatientswere54years28,30,32,35-40and47years28,30,36-40
in cases and controls, respectively; 42.6% (75 of 176) of
cases28,30,32,35-40 and 47.0% (206 of 438) of controls28,30,36-38,40
weremale.Amongstudies29,30,33,34using thepopulationascon-
trols, the mean age of included patients was 51 years in cases;
40.4% (21 of 52) of casesweremale,29,30,33,34 while age and sex
data were not reported for controls.
Four studies28,30,36,39 and2 studies30,36 reported themean
carbamazepinedosages in the case and control groups,which
Figure 1. FlowDiagram for Study Identification, Inclusion, and Exclusion
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SJS indicates Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.
Table 1. Characteristics of Studies Included in theMeta-analysis
Source Race/Ethnicity Nationality Control
No. Positive for HLA-B*1502/Total No.
Matching Criteria
Newcastle-
Ottawa Scale
ScoreCase Control
Alfirevic et al,14 2006 White European Matched 0/2a 0/43 Drug, hospital 4
Chang et al,27 2011 Multiethnic Mixed populationb Population 12/16 47/300 NR 4
Hung et al,28 2006 Asian Han-Chinese Matched 59/60 6/144 Drug, hospital 6
Kaniwa et al,29 2008 Asian Japanese Population 0/7c 0/493 NR 4
Kashiwagi et al,16 2008 Asian Japanese Population 0/2a 1/371 NR 4
Kim et al,30 2011 Asian Korean Population and
matched 1/7
2/485 For population
study, 0/50 for
matched study
NR for population study,
drug and hospital for
matched study
6
5
Liao et al,31 2009 Asian Han-Chinese Matched 6/6 16/76 Drug, hospital 5
Locharernkul et al,32 2008 Asian Thai Matched 6/6a,c 8/42 Drug, hospital 6
Lonjou et al,33 2008 Asian, white Mixed populationd Population 4/12c 1/1290 NR 4
Mehta et al,34 2009 Indian Indian Population 6/8 0/10 NR 4
Niihara et al,35 2012 Asian Japanese Matched 0/3 0/33 Drug, hospital 6
Shi et al,36 2012 Asian Han-Chinese Matched 13/18 12/93 Drug, hospital 6
Tassaneeyakul et al,37 2010 Asian Thai Matched 37/42 5/42 Drug, hospital 5
Then et al,38 2011 Asian Mixed populatione Matched 6/6 0/8 Drug, hospital 4
Wu et al,39 2010 Asian Han-Chinese Matched 8/8 4/50 Drug, hospital 5
Zhang et al,40 2011 Asian Han-Chinese Matched 16/17 2/21 Drug, hospital 5
Abbreviation: NR, not reported.
a Only patients who developed Stevens-Johnson syndrome or toxic epidermal
necrolysis were included.
bChinese, Indian, andMalaysian.
c Only patients who received carbamazepine were included. All 4 cases with
positiveHLA-B*1502were of Asian ancestry.
d European and Asian (Pakistan, Reunion, Vietnam, China, Cambodia, and India)
and African (Senegal).
e Chinese andMalaysian.
HLA-B*1502 Allele and Carbamazepine Therapy Original Investigation Research
jamadermatology.com JAMADermatology September 2013 Volume 149, Number 9 1027
Downloaded From: http://www.jamapeds.com/ by a UQ Library User  on 04/08/2014
were559mg/dand514mg/d, respectively.Onepopulationcon-
trol study30 reported this information,whichwas243mg/d for
the case group.
Most studies (8of 11 [72.7%])usingmatchedcontrols speci-
fied the use of criteria by Roujeau and Stern1 and by Roujeau
et al7 as SJS and TEN diagnostic criteria for cases, while 4
studies14,16,31,38 provided no information on the criteria used.
Among studies using population controls, 3 studies27,33,38 re-
ported use of the criteria by Roujeau and colleagues.1,7 In all
studieswithmatched controls, patientswithout SJS and TEN
who had used carbamazepine for at least 3 to 6 months were
included in the control group, while patients who developed
SJS and TENwithin 2 to 12 weeks after the start of carbamaz-
epine therapy were included in the case group.
Only 2 studies28,33 reported Hardy-Weinberg equilibrium,
and these confirmed no departure from equilibrium. Charac-
teristics of the alleles (heterozygous vs homozygous) in cases
andcontrolswere reported in2 studies.32,34All 6patients in the
study byMehta et al34 had a heterozygousHLA-B*1502 allele,
while 20of 21 patients in the studybyLocharernkul et al32 had
a heterozygous allele. Eleven studies16,27,30-34,36-38,40 identi-
fied HLA-B*1502 using polymerase chain reaction sequence-
specific primers, 3 studies28,29,39 used polymerase chain reac-
tionsequence-based typing, and2studies14,32usedpolymerase
chain reactionsequence-specificoligonucleotides.Noneof the
included studies described a blinding procedure for person-
nel performing the genotyping.
Quality Assessment
Themethodological quality of all studies was summarized as
a mean Newcastle-Ottawa Scale score of 5 (range, 4-6; maxi-
mum score, 9). These results are given in Table 1.
Quantitative Synthesis
Analysis UsingMatched Control Studies
Eleven studies16,27,30-34,36-38,40 were included in a compari-
sonof theHLA-B*1502 carrier frequencies in the cases andcar-
bamazepine-tolerant controls.Therewere 175SJSorTENcases
Table 2. Reported Odds Ratios for the Included Studies and Summary Odds Ratios Categorized
by Type of Study and by Race/Ethnicity
Source
No. Positive for HLA-B*1502/Total No.
Odds Ratio (95% CI)Case Control
Matched Control
White race/ethnicity
Alfirevic et al,14 2006 0/2 0/43 NA
Asian
Han-Chinese
Hung et al,28 2006 59/60 6/144 1357.00 (159.84-11 520.40)
Liao et al,31 2009 6/6 16/76 47.67 (2.55-890.45)
Shi et al,36 2012 13/18 12/93 17.55 (5.31-58.06)
Wu et al,39 2010 8/8 4/50 114.83 (6.25-2110.92)
Zhang et al,40 2011 16/17 2/21 152.00 (12.59-1834.92)
Subtotal (I2 = 71.3%, P = .008) NA NA 115.32 (18.17-732.13)
Thai
Locharernkul et al,32 2008 6/6 8/42 52.76 (2.70-1031.31)
Tassaneeyakul et al,37 2010 37/42 5/42 54.76 (14.62-205.13)
Subtotal (I2 = 0.0%, P = .98) NA NA 54.43 (16.28-181.96)
Korean
Kim et al,30 2011 1/7 0/50 23.31 (0.86-633.94)
Malaysian
Then et al,38 2011 6/6 0/8 221.00 (3.85-12 694.65)
Japanese
Niihara et al,35 2012 0/3 0/33 NA
Overall (I2 = 39.0%, P = .98) NA NA 79.84 (28.45-224.06)
Population Control
White race/ethnicity
Lonjou et al,33 2008 4/12 1/1290 644.50 (64.69-6431.36)
Indian
Mehta et al,34 2009 6/8 0/10 54.60 (2.25-1326.20)
Asian
Chang et al,27 2011 12/16 47/300 16.15 (4.99-52.22)
Kaniwa et al,29 2008 0/7 0/493 NA
Kashiwagi et al,16 2008 0/2 1/371 49.40 (1.59-1531.08)a
Kim et al,30 2011 1/7 2/485 40.25 (3.20-265.09)
Subtotal (I2 = 0.0%, P = .68) NA NA 20.64 (7.47-57.07)
Overall (I2 = 53.1%, P = .07) NA NA 57.56 (12.50-265.09)
Abbreviation: NA, not applicable.
a Odds ratio was estimated based on
the continuity correction for zero
events.46
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and 602matched controls. Of the controls, 53were carriers of
the allele, while a much larger proportion of the cases (152 of
175) carried the allele. We found a clear relationship between
HLA-B*1502 and carbamazepine-induced SJS and TEN (sum-
mary OR, 79.84; 95% CI, 28.45-224.06). Heterogeneity was
minimal (I 2 = 45.1%) andwas not significant by theQ statistic
(P = .07). Therewas no apparent publication bias byBegg test
(P = .92), Egger test (P = .23), or funnel plot.
Analysis Using Population Control Studies
Six studies16,27,29,30,33,34 with 52 SJS or TEN cases and 2949
population controls were included in a separate analysis of
carrier frequency to test the relationship between the
HLA-B*1502 genotype and carbamazepine-induced SJS and
TEN compared with the general population. Cumulative
carrier frequencies for these 6 studies were 23 of 52 for cases
and 51 of 2949 for population controls. The relationship
between the HLA-B*1502 genotype and carbamazepine-
induced SJS and TEN compared with the general population
was statistically significant (summary OR, 57.56; 95% CI,
12.50-265.09). Heterogeneity was present (I 2 = 53.1%,
P = .007). There was no apparent publication bias by Begg
test (P = .31) or Egger test (P = .81) and with a funnel plot.
Subgroup Analyses
Subgroup analysis in the selected matched control
studies14,28,30-32,35-40 according to race/ethnicity yielded
similar and significant findings. Carbamazepine-induced
SJS or TEN was associated with the HLA-B*1502 allele in
Han-Chinese,28 ,3 1 , 36 ,39 ,40 Thai,32 ,37 Korean,30 and
Malaysian38 patients. The summary ORs for Han-Chinese,
Thai, Korean, and Malaysian populations are given in
Table 2 and in Figure 2. The summary OR for Han-Chinese
was 115.32 (95% CI, 18.17-732.13), with I 2 heterogeneity of
71.3%. Such heterogeneity probably arose from a nonhomo-
geneous patient population from the north and south of
China.47 This was confirmed by a reanalysis that excluded
this study and yielded similar results (OR, 113.65; 95% CI,
44.20-292 . 22) but with much less heterogeneity
(I 2 = 14.4%). In the sole matched control study among indi-
viduals of white14 and Japanese35 race/ethnicity, no patients
carried the HLA-B*1502 allele.
Discussion
Our results indicate that the HLA-B*1502 allele is strongly
associated with increased risk of developing SJS and TEN in
patients using carbamazepine, especially Asians. This
severe adverse event could be prevented if genetic informa-
tion were known a priori. Physicians and policymakers
should consider our findings to support the implementation
of genetic testing before initiation of carbamazepine
therapy.
Data reveal a high risk of developing SJS and TEN among
carbamazepine users with HLA-B*1502. For Han-Chinese,
Thais,Koreans,andMalaysians, therisksofSJSandTENamong
carbamazepine users carrying the HLA-B*1502 allele are ap-
proximately 115-fold, 60-fold, 25-fold, and 220-fold in-
creases, respectively.
Figure 2. Random-EffectsMeta-analyses of Carbamazepine-Induced Stevens-Johnson Syndrome
and Toxic Epidermal Necrolysis Among Carriers of theHLA-B*1502Allele
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These observed racial/ethnic differences could be
explained by the fact that HLA-B*1502 may not be the only
gene associated with SJS and TEN in patients using carba-
mazepine. For example, another HLA allele (HLA-A*3101) is
related to SJS and TEN; the ORs for carriers of this gene using
carbamazepine are approximately 26-fold higher for
Europeans48 and 11-fold higher for Japanese.49 Furthermore,
Hung et al28 reported that HLA-A*3101 was associated with
carbamazepine-induced maculopapular eruptions (OR, 17.5;
95% CI, 4.6-66.5) and hypersensitivity syndrome (OR, 7.1;
95% CI, 3.1-16.5) in a Han-Chinese population. Similar to the
observed relationship between HLA-B*1502 and SJS and TEN
among carbamazepine users, there are some examples of
associations in which more than 1 gene has a major role.50,51
Although the mechanism by which HLA-B*1502 contrib-
utes to SJS and TEN among carbamazepine users is not fully
understood, it is well recognized that HLA-B molecules sup-
ply endogenous or processed exogenous antigens to T cells,
eliciting an adaptive immune response. It seems that a spe-
cific HLA allele is required for the activation of drug-specific
T cells by the culprit drug. The T-cell receptor of the effector
T cell is thought to recognize the drug-peptide complex
bound by the specific HLA-B molecule on the antigen-
presenting cell, resulting in the release of immune media-
tors and leading to robust adaptive immune reactions in
severe cutaneous reactions.52-54
Our systematic meta-analysis has several limitations.
First, this study focused only on the relationship between
the HLA-B*1502 allele and carbamazepine-induced SJS
and TEN. Other genes that may be associated with SJS
and TEN (such as HLA-A*3101) were excluded from our
study. Second, an article43 and 2 abstracts44,45 that poten-
tially met our study criteria were not included in the
meta-analysis because they did not provide the number
of control patients, which was important information
for the analysis. Third, only 2 studies28,33 among 16 articles
provided Hardy-Weinberg equilibrium information,
preventing us from assessing the representativeness of the
controls.
Our study reveals that HLA-B*1502 is strongly associ-
ated with the development of SJS and TEN. The prevalence
of HLA-B*1502 among residents of southeast Asian coun-
tries was reported to be 8%.9,55 This is against the back-
ground of a high incidence of SJS and TEN among this popu-
lation (8 cases per 1 million person-years).56,57 In Thailand,
Singapore, and Malaysia, carbamazepine use represents up
to one-third of all SJS and TEN cases.56-58 The relationship
between the HLA-B*1502 allele and carbamazepine-induced
SJS and TEN was strong in Thai (OR, 54.43) and Malaysian
(OR, 221.00) populations in our study, reflecting the high
disease risk associated with HLA-B*1502 carrier status
among patients of Asian ancestry. Because carbamazepine
use for epilepsy is normally a long-term therapy, the safety
requirements are high. It is important to consider genetic
screening among populations at high risk, such as those
from southeast Asian countries. However, there is a strong
need to consider other factors such as feasibility, ethical and
legal issues, and cost-effectiveness before implementation
of such genetic screening.
In conclusion, we found a strong relationship between
HLA-B*1502 and carbamazepine-induced SJS and TEN
in Han-Chinese, Thai, and Malaysian populations. Recogni-
tion of HLA-B allele status before initiation of the drug may
be beneficial to some groups of patients. Such information
will assist physicians in determining the optimal drug
therapy.
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NOTABLENOTES
Presidential Practice of Dermatology
Loren Zech, MD, PhD; Bryce Turner, BA; Scott A. Norton, MD, MPH
LyndonJohnson, the36thPresidentof theUnitedStates, hadmanyca-
reers en route to the White House (schoolteacher, local administrator,
naval officer, and elected public official), but his brief stint as an ama-
teur dermatologist is generally overlooked. Johnson’s unorthodox ap-
proach to treating severe facial acne was first tried while he was an un-
dergraduateatSouthwestTexasStateTeachers’College.Aclassmatewho
witnessed the episode is quoted verbatim in the first volume of Robert
Caro’s monumental biography of Johnson1:
One student, a Bohemian farm boy, was generally immune from practi-
cal jokes because hewas so “slow” and gullible—some students believed
hemight be slightly retarded—as tobe toodefenseless a target. This stu-
dent had a severe case of acne, and one evening, talking with Johnson,
… he said girls wouldn’t go out with him because of it.
Lyndon said to him that the curewas to get fresh cowmanure and put it
on your face. He said, “Oh, go on,” and Lyndon said, “Didn’t you ever turn
over a cow pile and see how white the grass was underneath, how the
manure bleached the grass?”… Lyndon tells him to take a towel and cut
eyeholes in it and wrap it around his face. He…came into our room and
asked how itwas, and Lyndon said, “You don’t have enough on to do any
good.”Hemadehimputmore on. In themorning, he smelled so bad, you
couldn’t go near him.
On the one hand, we do not have long-term follow-up of Johnson’s ini-
tial patient, and, as with many n-of-1 clinical trials, we lack adequate
data on safety and efficacy onwhich to base further recommendations.
Interest in alternative interventions for severe acne waned greatly with
the success of systemic retinoids. Furthermore, use of topical bovine
excrement would certainly test the limits of acceptability for today’s
discerning patients, even with a marketing strategy that touts its natu-
ral origins.
On the other hand, medicinal formulations of equine urine, porcine
digestivehormones,bovinebile, andotherbelow-the-diaphragmexcre-
tions are regularly used inmedicineandgenerally acceptedby thewider
public. Human feces, in the form of an allogeneic transplant, is now an
acceptedtreatment forClostridiumdifficileenteritis.2Evidenceof themi-
crobiome’s role in healthy and diseased skin, and its potential manipu-
lation in therapy, is piling up. Kang et al3 have shown that some human
fecal enterococci have in vitro activity against Proprionobacterium ac-
nes,which suggests further exploration of fecotherapy in dermatology.
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